Processa Pharmaceuticals, Inc. ((PCSA)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Processa Pharmaceuticals, Inc. is conducting a Phase 2 clinical study titled A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer. The study aims to evaluate the efficacy and safety of the combination of PCS6422 and capecitabine compared to capecitabine alone in patients with advanced or metastatic breast cancer who have limited treatment options.
The study tests two experimental regimens involving PCS6422 and capecitabine, an oral chemotherapy drug, against the standard dose of capecitabine. PCS6422 is an experimental drug designed to enhance the immune response when combined with capecitabine.
This interventional study is randomized with a parallel assignment model and is open-label, meaning no masking is involved. The primary purpose is to assess treatment efficacy.
The study began recruiting on August 21, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on June 18, 2025, indicating ongoing recruitment and study progress.
The outcome of this study could significantly impact Processa Pharmaceuticals’ stock performance by potentially expanding treatment options for breast cancer, a competitive field with several major players. Investors should watch for updates as positive results could enhance market confidence and drive stock value.
The study is ongoing, with further details available on the ClinicalTrials portal.